MedLife is strengthening its leading position in advanced diagnostics through the acquisition of a majority stake in Qualipat

- *MedLife Group acquires 75% of Qualipat and expands its expertise in pathological anatomy, immunohistochemistry, and molecular diagnostics.*
- *The partnership marks a new phase of development, focused on digital pathology, the integration of oncological biomarkers, and the use of artificial intelligence technologies to support medical practice.*
- *For patients, the integration of Qualipat into the MedLife Group means expanded access to advanced laboratory testing within a unique ecosystem in Romania, bringing together expertise in pathology, molecular biology, genomics, and microbiome analysis.*

Bucharest, August 20, 2026: MedLife, Romania's largest network of medical services and the operator with the largest investments in genetics and molecular biology, announces the signing of a transaction to acquire a 75% stake in Qualipat, a Romanian company specializing in pathological anatomy, immunohistochemistry, and molecular testing. Through this transaction, the Group consolidates its leading position in the field of advanced diagnostics and takes a new step toward the development of personalized medicine.

Founded in 2016, Qualipat operates in Timisoara and Oradea and offers services nationwide. The company has a team of 21 employees and recorded revenue of approximately 1.2 million euros in 2025, with a monthly average of about 3,000 patients.

One of the company's main strengths is its medical team and the experience it has gained in personalized pathological and oncological diagnostics. Qualipat's pathologists hold international certifications in the diagnosis and interpretation of biomarkers, a critical skill in the context of the rapid development of personalized medicine and targeted cancer therapies.

„Integrating Qualipat's expertise complements the investments we have made in recent years in genetics, genomics, and molecular biology. In oncology, value is created when information obtained from pathological anatomy, immunohistochemistry, molecular biology, and genetics is interpreted together. Through this partnership, we are strengthening our ability to build diagnostic services in Romania that meet standards comparable to those of major international centers and to support the development of personalized medicine

For patients, this means easy access to an advanced diagnostic ecosystem, where expertise in pathological anatomy and molecular biology is complemented by the MedLife Group's capabilities in genomics and microbiome analysis. "This represents a huge leap forward in terms of the level of expertise and technology available in Romania today. Correlating all this data lays the groundwork for more accurate diagnoses and therapeutic decisions tailored to each patient, in line with the principles of personalized medicine", **said Robert Beke, Executive Director of the MedLife Group Laboratory Network.**

Following the transaction, the company will continue to operate under the same brand, and Prof. Dr. Ovidiu Pop will remain in his position as General Manager to ensure medical and managerial continuity and guide the company's next phase of development.

Digital Pathology and AI Technologies for Standardizing Diagnosis

One of the main areas of development for the new partnership is accelerating the transition to digital pathology and integrating advanced artificial intelligence solutions into diagnostic processes. Joint plans include the use of FDA-validated software platforms for the interpretation and standardization of oncological biomarkers—technologies that can help increase diagnostic reproducibility and facilitate collaboration among specialists, regardless of their location.

At the same time, the company's integration into the Group's extensive diagnostic infrastructure will enable the development of medical workflows that connect pathological anatomy, immunohistochemistry, molecular biology, and genetics into a unified model for evaluating oncology cases. The goal is to obtain the most comprehensive picture possible of each patient's biological and molecular profile and to reduce the time required to access information relevant to treatment decisions.

„Joining the MedLife Group represents an opportunity to accelerate the projects developed in recent years and to expand access to infrastructure, technology, and multidisciplinary expertise. We aim to further advance modern pathology, digital pathology, and molecular diagnostics, while building centers of excellence based on physician subspecialization. We believe this integration will bring direct benefits to both the medical community and patients through faster, more standardized, and more accurate diagnostic services", **said Prof. Dr. Ovidiu Pop, CEO of Qualipat**.

In the medium term, the strategy aims to develop specialized diagnostic centers organized according to physicians' subspecialties and the main pathological areas. This model will allow for the concentration of medical expertise and the integration of information from pathological anatomy, immunohistochemistry, genetics, and molecular biology into a unified approach.

The new acquisition continues the MedLife Group's strategy of consolidating its leadership position in technology and advanced diagnostics by developing an integrated ecosystem that supports the transition to precision medicine, through both organic investments and strategic partnerships and acquisitions.

About the MedLife Group

MedLife was founded nearly three decades ago, has grown steadily, and has become the largest provider of private healthcare services in Romania. The Romanian entrepreneurs who founded this company invested and dedicated themselves to bringing about change in the Romanian healthcare system; they believed in innovation and dared to aim high to offer Romanian patients quality, professionalism, care, and respect for their needs.

The company operates the most extensive network of clinics, one of the largest networks of medical laboratories, general and specialized hospitals, and has the largest corporate client base for preventive health care packages in the country. It is also, in terms of sales, one of the largest private healthcare providers in Central and Eastern Europe.

The MedLife Group has a proven track record of success in both organic growth and growth through acquisitions. Its strong and experienced management team has been able to create and manage these growth opportunities, gaining valuable knowledge and experience that enable it to chart the best course for continued successful expansion.

As a Romanian company with a long tradition, MedLife chose to list on the Romanian Stock Exchange, serving as a model for listings on the local capital market. It has broadened horizons, and through its corporate governance practices, it has inspired other local companies to follow this path and contribute to the development of Romanian capital and the economy. The shares issued by MedLife SA are admitted to trading on the regulated spot market administered by the Bucharest Stock Exchange, Premium Category, under the ticker symbol "M."

During the pandemic, MedLife played a vital role in society and established itself as a leader in pandemic monitoring through its active involvement in research.

The company continues to invest in projects that benefit the local community, as well as in technology and infrastructure. It creates jobs and fosters an ecosystem that contributes to the development and maintenance of a healthy Romania.